Alexander Abreo

ORCID: 0009-0006-5615-5345
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune cells in cancer
  • Chemokine receptors and signaling
  • Acute Myeloid Leukemia Research
  • Inflammation biomarkers and pathways
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • Immunodeficiency and Autoimmune Disorders
  • RNA regulation and disease
  • Blood disorders and treatments
  • Immune Cell Function and Interaction
  • Congenital Diaphragmatic Hernia Studies

The Ohio State University
2023

University of New Orleans
2020

Abstract Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC express Bruton's tyrosine kinase (BTK) BTK inhibition ibrutinib, an FDA-approved irreversible inhibitor BTK, leads expansion/function mice significantly improves the antitumor activity anti-PD-1 antibody treatments. Single-cell RNA sequencing (scRNA-seq) was used characterize effect ibrutinib on gene expression...

10.1158/1541-7786.mcr-22-0572 article EN Molecular Cancer Research 2023-11-28

<div>Abstract<p>Myeloid-derived suppressor cell (MDSC) levels are elevated in patients with cancer and contribute to reduced efficacy of immune checkpoint therapy. MDSC express Bruton's tyrosine kinase (BTK) BTK inhibition ibrutinib, an FDA-approved irreversible inhibitor BTK, leads expansion/function mice significantly improves the antitumor activity anti-PD-1 antibody treatments. Single-cell RNA sequencing (scRNA-seq) was used characterize effect ibrutinib on gene expression...

10.1158/1541-7786.c.7100173.v1 preprint EN 2024-03-01
Coming Soon ...